Investors
Information Disclosure
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MARCH 20242024.04.02
-
ANNUAL RESULTS ANNOUNCEMENT FOR THE YEAR ENDED 31 DECEMBER 20232024.03.28
-
FINAL DIVIDEND FOR 20232024.03.28
-
VOLUNTARY ANNOUNCEMENT - APPROVAL FOR MARKETING OF “IOPROMIDE INJECTION”2024.03.25
-
VOLUNTARY ANNOUNCEMENT - UPDATE ON DEVELOPMENT PROGRESS OF MASH PRODUCTS "LANIFIBRANOR" AND "TQA2225"2024.03.15
-
VOLUNTARY ANNOUNCEMENT - DATA OF PHASE II CLINICAL STUDY OF KRAS G12C INHIBITOR "GARSORASIB TABLET (D-1553)" WILL BE PRESENTED AT 2024 AACR2024.03.13
-
VOLUNTARY ANNOUNCEMENT - DATA OF 5 STUDIES REGARDING "ANLOTINIB HYDROCHLORIDE CAPSULES" AND "TQB2916 (CD40 AGONIST)" WILL BE PRESENTED AT 2024 AACR2024.03.11
-
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 29 FEBRUARY 20242024.03.01